在瘤学临床试验中的间隔审查数据的RMST
Xiyuan Gao1, Tianmeng Lyu2, Menghao Xu3
1Department of Statistics, University of Missouri-Columbia, Columbia, Missouri, USA.
Statistics in medicine
|February 8, 2025
概括
限制平均存活时间 (RMST) 为瘤学试验中的危险比率提供了一个强大的替代方案. 新的方法准确地估计RMST与间隔审查的无进展生存 (PFS) 数据,比传统方法提高准确性.
科学领域:
- 生物统计学 生物统计学
- 临床瘤学临床瘤学
- 生存分析的分析.
背景情况:
- 在瘤学研究中,由于治愈的患者,延迟的治疗效果或切换,比例危险假设经常被违反.
- 限制平均存活时间 (RMST) 是临床上有意义的治疗益处的总结度量,避免了比例危险假设.
- 无进展生存 (PFS) 是一个常见的终点,但涉及疾病进展的间隔审查数据,复杂化分析.
研究的目的:
- 开发和评估用于估计RMST的新方法,使用混合的右边审查和间隔审查数据,这在瘤学终点中很常见,如PFS.
- 将这些新的RMST估计器的性能与使用模拟的传统方法进行比较.
- 研究评估频率,时间和限制时间点的选择对RMST估计的影响.
主要方法:
- 模拟研究使用各种瘤学试验场景进行,包括不同的评估频率和治疗效果大小.
- 建议用于RMST的替代估计和推断方法,考虑间隔审查数据.
- 根据不同患者访问时间表和时间限制评估RMST估计值.
主要成果:
- 结合间隔审查的RMST估计器被发现是不偏见的,比传统方法更准确.
- 在两组比较中,拟议估计器的表现与现有方法可比.
- RMST估计器的准确性受到预定评估计划和患者访问窗口的影响.
结论:
- 新的RMST估计方法为使用间隔审查PFS数据的瘤学试验提供了公正和更准确的结果.
- 这些先进的方法为传统方法提供了可靠的替代方案,特别是当比例危险假设值得怀疑时.
- 评估时间表和患者访问模式的选择显著影响RMST估计器的性能.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
127
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
127
01:24Kaplan-Meier Approach
80
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
80
01:19The Mantel-Cox Log-Rank Test
282
The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of...
282
01:09Censoring Survival Data
56
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
56
01:21Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
01:12Hazard Ratio
78
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
78